Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat
Authors:
- 1 January 2002
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 32 (11) , 975-984
Abstract
1. Midazolam is metabolized in the rat by CYP3A enzymes to 4-OH-midazolam (4-OH-MDZ) and 1'-OH-midazolam (1'-OH-MDZ). The induction of midazolam metabolism was studied in male Wistar rats treated with dexamethasone (50 mg kg−1 day−1) during 4 days via the oral or intravenous routes. Microsomes were prepared from the liver and the proximal small intestine and in vitro metabolism of midazolam was determined. In addition, CYP3A1- and CYP3A2-like protein levels were measured by gel electrophoresis and immunoblotting. 2. The Vmax's (mean SEM) for 4-OH-MDZ and 1'-OH-MDZ formation were much lower in intestinal (0.078 ± 0.002 and 0.074 ± 0.002 µM min−1 mg−1 protein, respectively) compared with hepatic microsomes prepared from the uninduced rat (0.870 ± 0.007 and 0.310 ± 0.020 µM min−1 mg−1 protein, respectively). Induction by oral or intravenous dexamethasone pretreatment led to significant increases in Vmax for 4-OH-MDZ and 1'-OH-MDZ by both intestinal and hepatic microsomes. Oral dexamethasone pretreatment via the oral route resulted in a more pronounced increase in Vmax compared with intravenous administration of the inducer. 3. CYP3A1 and CYP3A2 protein levels in liver microsomes were significantly increased following oral (3.7- and 3.2-fold, respectively) or intravenous (2.6- and 2.1-fold, respectively) pretreatment with dexamethasone. On the contrary, only oral dexamethasone pretreatment resulted in a significant change in intestinal CYP3A2-like protein (7.3-fold). A slight difference in the migration distance of the immunoreactive band for CYP3A2 was also observed for intestinal microsomes. 4. These results suggest that intestinal CYP3A enzymes in the rat differ from hepatic CYP3A1 and CYP3A2. They also demonstrate that systemic dexamethasone administration can induce intestinal microsome activity.Keywords
This publication has 15 references indexed in Scilit:
- In-vivo and In-vitro Metabolic Clearance of Midazolam, a Cytochrome P450 3A Substrate, by the Liver under Normal and Increased Enzyme Activity in RatsJournal of Pharmacy and Pharmacology, 1999
- A Novel Cytochrome P450 3A Isoenzyme in Rat Intestinal MicrosomesBiochemical and Biophysical Research Communications, 1999
- Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in ratsLife Sciences, 1998
- Sensitive assay for midazolam and its metabolite 1′-hydroxymidazolam in human plasma by capillary high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- Involvement of CYP3A1, 2B1, and 2E1 in C-8 hydroxylation and CYP 1A2 and flavin-containing monooxygenase in N-demethylation of caffeine: identified by using inducer treated rat liver microsomes that are characterized with testosterone metabolic patternsChemico-Biological Interactions, 1998
- IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3AAnnual Review of Pharmacology and Toxicology, 1998
- Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and InhibitorsDrug Metabolism Reviews, 1997
- Dietary ω3 fatty acids and cholesterol modify enterocyte microsomal membrane phospholipids, cholesterol content and phospholipid enzyme activities in diabetic ratsLipids, 1994
- Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamilyBiochemical Pharmacology, 1994
- Extrahepatic Metabolism of Drugs in HumansClinical Pharmacokinetics, 1994